tbuckley/cabot-search huggingface dataset:
Intravenous (IV)/intraperitoneal (IP) paclitaxel and IP carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: A feasibility study.
Authors: S. Nagao, T. Nishikawa, A. Kurosaki, R. Ohishi, N. Iwasa, K. Hasegawa, K. Fujiwara
Journal: Journal of Clinical Oncology (2011)

5054 Background: The purpose of this study is to evaluate the feasibility of IV / IP paclitaxel and IP carboplatin (TCipTip therapy) in patients with epithelial ovarian, fallopian tube or peritoneal carcinoma. Methods: From December 2007 to August 2010, the women with histologically confirmed, stage Ic-IVepithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma were received 6 cycle of TCipTip therapy after primary cytoreductive surgery. IV paclitacxel was administered at 135 mg/m2 followed by IP carboplatin administration based on the AUC = 6 on day1, and IP paclitacxel was administered at 60 mg/m2 on day 8. The toxicity grade was determined by CTCAE version 3.0. Progression free survival and Overall survival were estimated using Kaplan-Meier method. This study had been approved by the institutional review committee. The institutional review board required us to administer 45mg/m2 of IP paclitaxel at first cycle for the first 3 women to make sure the safety. Results: Twenty women entered in this study. They included 18 epithelial ovarian carcinomas (stage Ic, 8; stage IIc, 2; stage IIIc, 7; stage IV, 1), 1 stage IIc fallopian tube carcinoma and 1 stage IV primary peritoneal carcinoma. There were 12 serous, 5 endometrioid, 1 mucinous, 1 clear cell adenocarcinoma, and 1 mixed carcinoma. Eleven women achieved optimal status at primary surgery. Incidences of grade 3/4 hematological toxicities were 73% for neutrocytopenia, 9% for thrombocytopenia, and 24% for anemia. Observed grade 3/4 non-hematological toxicities were 4 for grade 3 allergy, 1 for grade 3 ileus. Ten patients completed more than 6 cycles of chemotherapy. The reasons of interruption were 3 for allergy to paclitaxel, 2 for abdominal pain, 1 for allergy to carboplatin, 1 for disease progression, 1 for pleural embolism, 1 for ileus, 1 for change of address. The PFS and OS at 2years were 85% and 47%, respectively. Conclusions: The toxicities by TCipTip therapy were acceptable, and this therapy is feasible for patients with epithelial ovarian carcinoma, fallopian tube carcinoma or peritoneal carcinoma. Further evaluation about TCipTip therapy is warranted.
Can prognostic factors identify women receiving anthracycline plus cyclophosphamide-based chemotherapy (MEC) who do not require an NK<sub>1</sub> receptor antagonist?
Authors: D. Warr, J. C. Street, A. D. Carides
Journal: Journal of Clinical Oncology (2009)

e20502 Background: Age, alcohol use, and history of sickness associated with pregnancy or motion have been identified as risk factors for chemotherapy-induced emesis. This post hoc analysis addressed two questions: 1) Can prognostic factors identify a low risk group for whom ondansetron (OND) plus dexamethasone [D] alone provide a high level of protection (≥80% no emesis)? 2) Does the NK 1 receptor antagonist aprepitant improve antiemetic outcome regardless of emetic risk? Methods: The analysis was based upon outcomes in patients with breast cancer enrolled in a Phase III double-blind, placebo-controlled trial randomized to Day 1 OND 8 mg and D 20 mg before chemotherapy and OND 8 hours later and OND 8 mg bid Days 2–3 vs. Day 1 aprepitant 125 mg PO, OND 8 mg, and D 12 mg before chemotherapy and OND 8 mg 8 hours later and aprepitant 80 mg PO qd Days 2–3. Multivariate logistic regression models were used to assess the impact on emesis of the regimen with aprepitant, and previously reported risk factors, including age (&lt;55 and ≥55 years), ethanol use (0–4 or ≥5 drinks/week), history of pregnancy-related morning sickness, and history of motion sickness, using a modified intent-to-treat approach. Results: 856 patients were assessed for efficacy. Treatment with aprepitant (p&lt;0.0001), older age (p=0.006), ethanol use (p=0.0048), and no history of morning sickness (p=0.0007) were all significantly associated with reduced likelihood of emesis; motion sickness was not a risk factor. The Table below shows the probability of no emesis associated with the presence of 0, 1, 2, or all of these factors in the aprepitant and active control arms. Conclusions: 1) The low-risk group identified by this analysis is of questionable utility because it comprised less than 3% of patients. 2) We could not confirm that motion sickness was a significant risk factor. 3) Aprepitant improved the control of emesis irrespective of the number of risk factors for emesis. [Table: see text] [Table: see text]
Effect of daily pollution exposure in the autonomic system in traffic workers of Sao Paulo
Authors: Daniel Alveno, Milene Saccomani, Felipe Mendes, Paulo Saldiva, Celso Carvalho
Journal: European Respiratory Journal (2011)

Background: Heart rate variability is used to quantify autonomic response and to detect cardiovascular diseases. Chronic pollution exposure is known to increase arterial pressure and the incidence of cardiac ischemia leading to cardiovascular diseases and death; however the effect of variation of daily pollution in chronically exposed subjects remains poorly known.

Objective: To study the effect of acute pollution exposition in the autonomic system at rest and exercise in traffic workers.

Methods: Twenty-one male subjects were studied in 4 randomized working days (once a week) with distinct pollution exposure. The amount of pollution (ozone (O3) and nitrogen dioxide (NO2)) was measured 24 hours before the day test by a pollution analyzer. Activity of autonomic system response was measured during 5 minutes either at rest or during treadmill exercise (moderate intensity).

Results: The levels of exposure pollution were considered intermediate and ranged from 133.9 μg/m3 to 317.2μg/m3 and 0.1μg/m3 and 26.3 μg/m3 (respectively, of NO2 and O3). In the days with higher levels of pollution, it was observed a reduction in the activity parasympathetic system (RMSSD) at rest (p<0.05). In addition, it was observed a linear correlation between the levels of pollution and a reduction in the RMSSD measure at rest (r=0.52; p=0.01). Interesting, during exercise, the parasympathetic response was increased in the most polluted days (p<0.05).

Conclusion: Our results suggest that even low changes in daily pollution exposure selectively modify the autonomic system to either rest of exercise.

Supported by CNPq.
Abstract 15404: Changes in Atrial Fibrillation Cycle Length in the Pulmonary Vein by Endocardial High-Frequency Stimulation Before and After Ganglionated Plexus Ablation
Authors: Mitsuru Takami, Kohei Yamashiro, Yuichiro Sakamoto, Koyo Satoh, Takahiko Suzuki
Journal: Circulation (2012)

Introduction: Experimental and clinical studies suggest that ganglionated plexus (GP) activation plays a significant role in the initiation and maintenance of atrial fibrillation (AF). In animal su...
Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion.
Authors: Lee M. Krug, Marjorie Glass Zauderer, Prasad S. Adusumili, Erin McGee, Kent Sepkowitz, Mark Klang, Yong A. Yu, Paul Scigalla, Valerie W. Rusch
Journal: Journal of Clinical Oncology (2015)

7559 Background: GL-ONC1 is an attenuated vaccinia virus genetically engineered with the insertion of RUC (luciferase)-GFP, LacZ (beta-galactosidase), and gusA (beta-glucuronidase) genes. We investigated the feasibility, safety, and recommended dose of GL-ONC1 when administered intrapleurally. Methods: Pts with pleural effusion from malignant pleural mesothelioma (MPM), NSCLC, breast cancer, or other solid tumor, and a free pleural space were eligible. Single doses of 1x107, 1x108, 1x109, or 3x109 plaque forming units were administered, and escalation used a 3+3 design. Virus was infused with 500cc Ringer's Lactate over 1hr through a pleural catheter. Fluorescent-imaging guided, thoracoscopic pleural biopsies were performed 2-9 days later. Blood, sputum, urine, and pleural fluid were analyzed for viral shedding by viral plaque assays (VPA). No chemotherapy or radiation was administered during the course of the study (-14 days to 60 days). Results: 14 pts have been treated: MPM (11), NSCLC (2), breast (1). Among 13 evaluable pts (1pt with NSCLC was not evaluable due to the rapid development of brain metastases) no dose limiting toxicities occurred. The most common toxicities were fever (7 pts), chills (6), and flu-like symptoms (5), all grade 1/2 occurring mostly in the 24hr after infusion. One patient at dose level 4 had transient grade 3 AST/ALT elevation. 1/28 urine and 5/28 pleural fluid post-treatment samples had +VPA. Positive GL-ONC1 infection of tumor specimens was identified in 6 of 8 pts with epithelioid MPM based on VPA, IHC and GFP imaging. 5 of the 9 pts with epithelioid MPM had time to progression ≥ 9 mo (18 mo in one pt). Pts with NSCLC and breast cancer progressed quickly at metastatic sites. Conclusions: Single dose, intrapleural administration of GL-ONC1 is safe, but is best suited for patients with MPM whose disease is limited to the pleura. We are now exploring multi-day treatment, and also treatment in conjunction with pleurectomy for pts with MPM. Supported by Genelux Corporation (NCT01766739). Clinical trial information: NCT01766739.
Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine.
Authors: M S Mitchell, P E Liggett, R L Green, J Kan-Mitchell, A L Murphree, G Dean, L Spears, F Walonker
Journal: Journal of Clinical Oncology (1994)

PURPOSE To determine whether active specific immunotherapy with lysates of cutaneous melanoma cells, administered with immunologic adjuvant DETOX (Ribi ImmunoChem Research, Inc, Hamilton, MT), is effective in shrinking a primary choroidal melanoma, in an elderly patient already blind in the nontumorous eye. An 81-year-old man was referred with a primary choroidal melanoma of the left eye, with virtual blindness of the right eye due to macular degeneration. He was begun on active specific immunotherapy with an experimental melanoma vaccine (melanoma theraccine) and DETOX on weeks 1, 2, 3, 4, and 6, respected after a hiatus of 2 weeks. After a response was noted, monthly injections were given. RESULTS The patient had a significant shrinkage of his choroidal melanoma from a height of 4.2 mm to 2.4 mm within 2 months. This was sustained by continual treatment for 21 months until September 1991. After the patient failed to return for 9 months while recuperating from a stroke, the lesion regrew to a height of 3.7 mm and developed an additional lobe. On resumption of monthly treatments, the lesion shrank to 3.4 mm within 3 months, lost the additional lobe, and has since remained stable. No metastases have been found over a period of nearly 4 years on quarterly computed tomographic (CT) scanning of the chest and abdomen, and magnetic resonance imaging of the head. CONCLUSION Active specific immunotherapy with cutaneous melanoma lysates has caused a clinically useful protracted regression of a primary choroidal melanoma in an elderly patient in whom surgery and radiation therapy were contraindicated. This may represent the first case of a primary choroidal melanoma, and perhaps the only primary tumor, successfully treated with systemic immunotherapy alone. A formal trial of active specific immunotherapy for primary choroidal melanoma in selected patients may be warranted.
TCT-512 Bioabsorbable Vascular Scaffold Radial Expansion and Conformation Compared to a Metallic platform: Insights from In-vitro Expansion in a Coronary Artery Lesion Model
Authors: Nicolas Foin, Renick D. Lee, Christos Bourantas, Alessio Mattesini, Nicole Soh, Ryo Torii, Jie En Lim, Enrico Fabris, Gianluca Caiazzo, Ismail D. Kilic, Ricardo Petraco, Sayan Sen, Sukhjinder S. Nijjer, Yoshinobu Onuma, Justin E. Davies, Carlo Di Mario, Philip Wong, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2015)
Sodium activation kinetics of red blood cell Na+/Li+ countertransport in diabetes
Authors: M Canessa, G Zerbini, L M Laffel
Journal: Journal of the American Society of Nephrology (1992)

Although many studies report an elevated Vmax of red blood cell Na/Li countertransport (CTT) activity in patients with insulin-dependent diabetes mellitus (IDDM) complicated by renal disease, divergent reports exist. This article reviews the technical issues and selection criteria that fuel this controversy. In addition, new studies from this laboratory indicate that insulin in vitro and in the nonfasted state modulate CTT activity and may contribute to the discrepant findings. Incubation of red blood cells from fasted controls with physiologic concentrations of insulin induced a twofold increase in the Km for external Na+. Similarly, Na+ activation kinetics of Li+ efflux showed saturation between 50 and 150 mM Na+ in fasted controls whereas saturation, postprandially, occurred between 100 and 150 mM Na+ as a result of an increase in Km. To clarify the role of prandial status on the measurement of Na+/Li+ CTT activity in diabetes, Na+ activation kinetics were investigated in 34 nonfasting patients with IDDM. Li+ efflux was fully saturated between 80 and 150 mM Na+ in the normoalbuminuric subjects (N = 22), whereas saturation occurred between 150 and 280 mM Na+ in the patients with diabetic nephropathy (N = 14). Patients with nephropathy have higher values of Km for Na+ than do the patients free of renal complications (86 +/- 9.5 versus 41.3 +/- 3.4 mM Na+, respectively; P < 0.000012). The higher Km prevented complete saturation of Li+ efflux at 150 mM extracellular Na+ concentration and contributed to the underestimation of Vmax at 150 mM Na+ selectively in persons with renal complications.(ABSTRACT TRUNCATED AT 250 WORDS)
단일 병원에서 경험한 최근 급성 바이러스간염의 원인 및 임상 양상
Authors: 강형민 ( Hyung Min Kang ), 정숙향 ( Sook Hyang Jeong ), 김진욱 ( Jin Wook Kim ), 이동훈 ( Don Hun Lee ), 최창규 ( Chang Kyu Choi ), 박영수 ( Young Soo Park ), 황진혁 ( Jin Hyuk Hwang ), 김나영 ( Na Young Kim ), 이동호 ( Dong Ho Lee )
Journal: Clinical and Molecular Hepatology (2007)

배경 및 목적: 급성 바이러스간염은 거의 전부가 A, B, C, D, E형간염바이러스(HAV, HBV, HCV, HDV, HEV)에 의해 발생한다. 우리 사회에서도 꾸준히 급성 바이러스간염이 발생하고 있지만, 각각의 원인에 따른 발생 빈도나 임상 양상에 대한 국내 연구가 부족한 실정이다. 이번 연구의 목적은 최근 국내 급성 바이러스간염의 원인 및 임상 양상에 대해 알아보고자 단일 기관의 경험을 정리하였다. 대상 및 방법: 2005년 5월부터 2006년 8월까지 분당서울대학교병원 내과에서 급성 바이러스간염으로 진단받은 55명의 환자를 대상으로 원인과 임상 양상을 전향적으로 조사하였다. 결과: 급성 바이러스간염의 원인으로 A형간염이 31명(56.4%)으로 가장 많았고, B형간염이 7명(12.7%), C형이 10명(18.2%), E형이 5명(9.1%)이었으며, 그 외에 A형과 E형이 동반된 경우 1명, 만성 C형간염에 급성 A형 간염이 동반된 경우가 1명이었다. 전체 대상 환자의 남녀 성비는 1.29:1이었고, 원인 바이러스에 따른 간염 환자들의 평균 나이는 A형간염이 29.1±4.4세, B형간염이 38.7±11.7세, C형간염이 45.3±17.6세, E형간염은 32.4±6.6세였으며, A형간염 환자의 평균 나이가 C형간염 환자들에 비해 유의하게 낮았다 (P=0.018). 급성 B형 간염 환자 7명 모두 만성 간염으로 이행하지 않고 회복이 되었다. 급성 C형간염 환자의 10명 중 4명(40%)이 만성 간염으로 진행하였다. E형간염 중 1명에서는 배우자의 동남아 여행력이 있었으나, 나머지 4명은 유행지역으로의 여행력이 없었고 임상 경과는 A형간염과 유사하였다. 결론: 최근 국내 급성 바이러스간염의 가장 많은 원인은 HAV였다. HCV와 HBV에 의한 급성 간염도 꾸준히 발생하고 있고 급성 E형간염도 드물지 않게 발생하였는데, 흥미롭게도 A형간염과 E형간염의 중복 감염 예가 관찰되고 있었다. 향후 급성 바이러스간염의 임상 양상을 알아보는 대규모의 연구가 필요하고, 이에 근거한 예방대책의 수립이 필요하다.
Phylogeny of some ascaridoid nematodes, inferred from comparison of 18S and 28S rRNA sequences.
Authors: S A Nadler
Journal: Molecular Biology and Evolution (1992)

Reverse transcription of cellular RNA was used to obtain sequences from regions of 18S and 26/28S ribosomal RNA for eight species of ascaridoid nematodes. Phylogenetic relationships among these species were inferred from the aligned sequences by maximum-parsimony and maximum-likelihood methods. Seventy-nine of the 168 sites that varied were phylogenetically informative in parsimony analysis. Phylogenetic inference based on maximum-likelihood analysis of all sequence sites yielded a tree of topology similar to that of the parsimony result. Monophyletic groups that were strongly supported by bootstrap resampling of these data included species constituting the Ascaridinae, as well as those representing the Toxocarinae. Alternative topologies that included a member of the Ascaridinae with the Toxocarinae were rejected statistically on the basis of analysis of the mean and variance of parsimony step differences between trees. The conformance of these sequence data to a molecular-clock model of evolution was evaluated statistically by a maximum-likelihood approach. The inferred rate of rRNA sequence change along the branch leading to Parascaris equorum is not consistent with a clocklike model of evolution.
Involvement of Na+/Ca2+ Exchanger in Inside-Out Signaling Through the Platelet Integrin IIbβ3
Authors: Masamichi Shiraga, Yoshiaki Tomiyama, Shigenori Honda, Hidenori Suzuki, Satoru Kosugi, Seiji Tadokoro, Yuzuru Kanakura, Kenjiro Tanoue, Yoshiyuki Kurata, Yuji Matsuzawa
Journal: Blood (1998)
Cancer prevalence in kidney transplant recipients in two general hospitals from Peru
Authors: B. E. Beltran, D. Morales, M. Medina, J. Espejo, R. Castillo, L. Riva, F. Hurtado de Mendoza, E. Salinas, A. Carrasco, J. Malaga
Journal: Journal of Clinical Oncology (2007)

21155 Background: Malignancy following kidney transplantation is an important medical problem during long-term follow-up. The accrual risk is approximately 100 times greater than the general population. We report some features of the cancers developed in our patient population Methods: We retrospectively reviewed records of 1050 kidney transplant recipients who received both unrelated or related allograft transplants from January 1972 to April 2006 and recorded the incidence of de novo malignancies that developed in this cohort. The study was carried out in two centers in Peru. The statistical method was descriptive and parametrical. Survival was calculated using the Kaplan-Meier method. Results: Forty-six cancer were diagnosed in 42 recipients (4.3%). Twenty six were men and 16 women, mean age was 46.0 years old (range:17–67). Malignancy was diagnosed between 2 to 240 months after transplantation. The tumors included Kaposi's sarcoma (KS) in ten patients, squamous cell carcinoma (SCC) in seven, basal cell carcinoma (BCC) in six, cervix cancer in four, colon and breast cancer in three and hepatocarcinoma in two. Also they were reported one case of small intestine cancer, osteosarcoma, pancreatic cancer, lung cancer, bladder cancer, schwanoma, melanoma, tongue cancer, postransplant lymphoproliferative disease, pelvis renal cancer and carcinomatosis from unknown primary. Thus, KS was the most common malignancy encountered in our series, with a prevalence of 0.95%, followed by SCC observed in 0.66% and BCC found in 0.57% of the patients. The average latency period between transplantation and development of malignancy was 25 months for KS, 72.0 months for SCC and 36.0 months for BCC. KS occurred earlier compared with the other cancers ( P &lt; 0.05); We failed to demonstrate any correlation between age/sex and specific type of cancer. The 10 year - survival was 71%. Conclusions: The prevalence of cancer in our renal transplant recipients was 4.3%. KS and non melanoma skin cancer were the most frequent cancer. Low incidence of postransplant lymphoproliferative disease was found. No significant financial relationships to disclose.
Abstract 356: KChIP2 Mediates Ion Channel Dysregulation by Novel Transcriptional Regulation of miR-34s
Authors: Drew Nassal, Haiyan Liu, Xiaoping Wan, Angelina Ramirez-Navarro, Eckhard Ficker, Isabelle Deschenes
Journal: Circulation Research (2014)

Introduction: Cardiac ion channel dysregulation is a hallmark of heart failure. Consistently, the disease yields dramatic decline in Ito through loss in Kv4 and its auxiliary partner KChIP2. Notably, transcriptional changes in heart failure can be elicited through KChIP2 silencing without disease signaling, suggesting potential transcriptional capacity for KChIP2. Further, disparity between resulting transcript and protein patterns suggests a mechanism compatible with modified miRNA activity. Considering other members of the KChIP family behave as transcriptional repressors, we hypothesize that KChIP2 regulates discrete miRNAs which in turn regulate cardiac excitability. Methods and Results: A miRNA microarray was conducted on neonatal rat ventricular myocytes (NRVM) following in vitro silencing of KChIP2 by siRNA, identifying the miR-34 family as potential transcriptional targets of KChIP2. Regulation, confirmed by quantitative PCR, showed reduction in miR-34a/b/c when over-expressing KChIP2 and increase following silencing. Luciferase assays were performed on the cloned promoter for miR-34b/c which reinforced direct KChIP2 repression on the miR-34b/c promoter. Furthermore, chromatin immunoprecipitation followed by PCR identified physical interaction of KChIP2 to the promoter site. Previous studies show modified expression of KChIP2 can lead to changes in several ion channel subunits. Therefore, we investigated if this was the consequence of KChIP2 regulation via miR-34. miR-34a/b/c precursors were expressed in NRVM which reduced transcript levels of Nav1.5 and Navβ1, and reduced protein levels for Kv4.3. Reflecting these changes, peak INa was reduced following miR precursor treatment. NRVMs were exposed to 100 μM phenylephrine for 48 hrs, significantly reducing KChIP2, Nav1.5, Navβ1, and Kv4.3, while elevating miR-34b/c. Returning KChIP2 expression by adenovirus normalized these changes back towards baseline, implicating the physiologic relevance of this pathway. Conclusion: These observations describe a novel mechanism where KChIP2 regulates a host of cardiac genes through transcriptional control of miRNAs, potentially explaining electrical remodeling observed in disease states where KChIP2 is reduced.
Intraperitoneal therapy in ovarian cancer: time's not up.
Authors: F M Muggia, D S Alberts
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.8.1510 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2072150 Intraperitoneal therapy in ovarian cancer: time's not up. F M MuggiaxF M MuggiaSearch for articles by this author , D S AlbertsxD S AlbertsSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.8.1510 PDF "Intraperitoneal therapy in ovarian cancer: time's not up.." Journal of Clinical Oncology, 9(8), pp. 1510–1511© 1991 by American Society of Clinical Oncology